Cystinuria

Introduction

Introduction to Cystinuria

Cystinuria is an inherited autosomal recessive disorder characterized by impaired transport of cystine and dibasic amino acids (ornithine, arginine, and lysine) in the proximal renal tubule and intestinal epithelium. This defect leads to excessive urinary excretion of cystine, which is poorly soluble in urine, resulting in the formation of recurrent renal stones. Cystinuria is one of the most common inborn errors of amino acid transport, with a prevalence of approximately 1 in 7,000 individuals worldwide.

Genetic and Molecular Basis

Cystinuria is caused by mutations in the genes encoding the subunits of the heterodimeric amino acid transporter system, specifically SLC3A1 (encoding rBAT) and SLC7A9 (encoding b⁰,⁺AT). These transporters are responsible for the reabsorption of cystine and dibasic amino acids in the kidney and intestine. Mutations in these genes disrupt transporter function, leading to the hallmark biochemical feature of cystinuria: elevated urinary cystine levels.

Study

Pathophysiology of Cystine Stone Formation

Cystine is a dimer of two cysteine molecules linked by a disulfide bond. Under normal physiological conditions, cystine is reabsorbed in the proximal renal tubule. In cystinuria, defective transport leads to high concentrations of cystine in the urine. Due to its low solubility at physiological pH, cystine precipitates and forms hexagonal crystals, which aggregate into renal stones. These stones can cause obstruction, infection, and chronic kidney disease if left untreated.

Clinical Presentation and Diagnosis

Patients with cystinuria typically present with recurrent nephrolithiasis, often beginning in childhood or early adulthood. Symptoms include renal colic, hematuria, and urinary tract infections. Diagnosis is confirmed by the presence of hexagonal cystine crystals in the urine sediment or elevated urinary cystine levels (>250 mg/g creatinine). Genetic testing for mutations in SLC3A1 and SLC7A9 can provide definitive diagnosis and guide family counseling.

Biochemical and Genetic Classification

Cystinuria is classified into three types based on genetic and biochemical findings. Type A results from mutations in both alleles of SLC3A1, leading to severe urinary cystine excretion. Type B is caused by mutations in SLC7A9 and is associated with variable clinical severity. Type AB, the rarest form, involves mutations in both genes. This classification helps predict disease severity and recurrence risk in affected families.

Management and Therapeutic Strategies

Management of cystinuria focuses on preventing stone formation through increased fluid intake to dilute urinary cystine, urinary alkalinization (e.g., with potassium citrate) to enhance cystine solubility, and dietary modifications to reduce methionine intake. Pharmacological agents such as tiopronin or D-penicillamine can be used to form more soluble drug-cysteine complexes. In refractory cases, surgical intervention may be required to remove large or obstructive stones.

Metabolic and Nutritional Considerations

Cystine is derived from the essential amino acid methionine, which is metabolized to cysteine and subsequently oxidized to cystine. Patients with cystinuria are advised to limit dietary methionine (found in animal proteins) to reduce cystine production. However, excessive protein restriction must be avoided to prevent malnutrition. Supplementation with vitamin C may also be considered, as it can reduce cystine to the more soluble cysteine form.

Summary

Key Takeaways

Cystinuria is an autosomal recessive disorder caused by mutations in SLC3A1 or SLC7A9, leading to defective renal and intestinal transport of cystine and dibasic amino acids. The hallmark of the disease is recurrent nephrolithiasis due to the precipitation of poorly soluble cystine in the urine. Early diagnosis and lifelong management are critical to prevent complications such as chronic kidney disease.

Clinical Correlate

Clinicians should suspect cystinuria in patients with recurrent renal stones, particularly those with a family history of nephrolithiasis or onset in childhood. Urinalysis revealing hexagonal crystals is pathognomonic, and 24-hour urine studies can quantify cystine excretion. Genetic counseling is recommended for affected families, as cystinuria follows an autosomal recessive inheritance pattern.

Future Directions

Research into cystinuria is focused on developing targeted therapies to restore transporter function or enhance cystine solubility. Gene therapy and novel pharmacological agents are being explored as potential treatments. Additionally, advances in genetic testing may improve early diagnosis and personalized management strategies for affected individuals.